Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care dataResearch in context

• Hauptverfasser: Brendon L. Neuen (Verfasst von), Min Jun (Verfasst von), James Wick (Verfasst von), Sradha Kotwal (Verfasst von), Sunil V. Badve (Verfasst von), Meg J. Jardine (Verfasst von), Martin Gallagher (Verfasst von), John Chalmers (Verfasst von), Kellie Nallaiah (Verfasst von), Vlado Perkovic (Verfasst von), David Peiris (Verfasst von), Anthony Rodgers (Verfasst von), Mark Woodward (Verfasst von), Paul E. Ronksley (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2024-02-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Summary: Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney failure and death in patients with chronic kidney disease (CKD) but are underused. We evaluated the number of patients with CKD in Australia that would be eligible for treatment and estimated the number...